The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Metabolomics Global Market Report 2024, the metabolomics market is expected to show promising growth in the forecast period.

The metabolomics market has witnessed a remarkable surge in recent years, with its size catapulting from $3.11 billion in 2023 to an anticipated $3.6 billion in 2024, boasting a robust Compound Annual Growth Rate (CAGR) of 15.8%. This expansion in the historic period is accredited to various factors, such as healthcare advancements, drug discovery and development, disease biomarker identification, contributions from academic and research institutions, and breakthroughs in nutrition and food science.

Future Projections
Looking ahead, the metabolomics market is poised for even more substantial growth, with a projected size of $6.68 billion in 2028, demonstrating a promising CAGR of 16.7%. The forecasted period’s growth is driven by key factors including personalized healthcare, drug safety and efficacy, microbiome and gut health exploration, environmental and agricultural applications, and advancements in regenerative medicine. Major trends to watch in this period encompass integration with other omics, targeted metabolomics, single-cell metabolomics, as well as the increasing role of data analytics and artificial intelligence, alongside a rise in point-of-care testing.

Cancer Prevalence Fueling Metabolomics Innovations

Global Impact of Cancer
A major catalyst for the metabolomics market surge is the escalating prevalence of cancer worldwide. Metabolomics plays a pivotal role in early cancer diagnosis, screening potential biomarkers to gauge drug responsiveness and facilitate timely intervention. Shockingly, according to a 2021 WebMD report, a staggering 10 million people succumbed to cancer globally. In the U.S. alone, the American Cancer Society projects 1.9 million new cases and 609,360 deaths in 2022, averaging 1,670 fatalities daily.

Metabolomics Approaches in Cancer Research
Metabolomics techniques, such as nuclear magnetic resonance (NMR) and mass spectrometry (MS), have become integral in cancer research. Renowned companies like Metabolon Inc., Bruker Corp., and others have embraced metabolomics, leveraging tools for early cancer detection and therapeutic advancements. In a bid to combat this global health crisis, these companies are at the forefront of utilizing metabolomics to drive breakthroughs in cancer diagnostics and treatment.

View More On The Metabolomics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Elevating Metabolomics Excellence: Thermo Fisher Scientific’s Collaborative Approach with the University of California

Strategic Partnerships in Metabolomics
Major players in the metabolomics market are strategically aligning to fortify their positions. Thermo Fisher Scientific Inc., a leading entity in the field, collaborated with the University of California to establish the Center of Excellence in Clinical Metabolomics. Launched in July 2021, this collaborative research initiative aims to standardize efforts within the metabolomics community, fostering large-scale cohort investigations and clinical research.

Center of Excellence Objectives
The Center of Excellence in Clinical Metabolomics, a joint venture between Thermo Fisher Scientific Inc. and the University of California, focuses on providing large-scale population-based metabolic analysis. This initiative includes standardized procedures, workflows for end-to-end metabolic profiling, customized chromatography-mass spectrometry (LC-MS) techniques, analytical control protocols, and training sessions for metabolomics professionals. The University of California, a public grant research university, brings its academic prowess to this transformative partnership.

Strategic Acquisition Boosts Clinical Microbiomics Metabolomics Capabilities

Innovation Through Acquisition
In a noteworthy move, Denmark-based Clinical Microbiomics acquired MS-Omics in October 2022, augmenting its metabolomics capabilities. The undisclosed acquisition added specialized metabolic profiling offerings to Clinical Microbiomics’ portfolio, advancing its systems biology platform and facilitating global research initiatives. MS-Omics, the acquired company, further solidifies Denmark’s position as a hub for metabolomics excellence.

Market Segmentation
The metabolomics market is intricately segmented to cater to diverse needs. The segmentation includes:

1. By Product & Service: Metabolomics Instruments, Metabolomics Bioinformatics Tools & Services
2. By Indication: Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors of Metabolism, Other Indications
3. By Application: Biomarker Discovery, Drug Discovery, Toxicology Testing, Nutrigenomics, Functional Genomics, Personalized Medicine, Other Applications

Regional Dominance
In 2023, North America emerged as the largest region in the metabolomics market, further underscoring the global significance and prominence of this evolving field.

Request A Sample Of The Global Metabolomics Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=2497&type=smp